生物樣本庫市場 - 全球產業規模、佔有率、趨勢、競爭、機會和預測，按類型、樣本類型、應用、最終用戶、地區和競爭細分，2019-2029F

2023 年全球生物樣本庫市場估值為 753.4 億美元，預計在預測期內將強勁成長，到 2029 年複合年成長率為 8.54%。生物樣本庫作為儲存各種類型生物樣本（包括血液、組織、細胞和 DNA）以及相關資料（例如病史和生活方式資訊）的儲存庫。這些儲存庫在推進生物醫學研究方面發揮著至關重要的作用，使科學家能夠獲得大量多樣化的樣本來研究疾病、識別生物標記和開發新療法。推動全球生物樣本庫市場成長的關鍵驅動力之一是癌症、心血管疾病和神經系統疾病等慢性疾病的盛行率不斷上升。需要來自不同患者群體的經過充分錶徵和註釋的生物樣本對於了解疾病機制、發現新的治療標靶和評估治療反應至關重要。此外，生物樣本庫技術的進步，包括自動化、機器人技術和資料管理系統，正在提高生物樣本庫營運的效率、可擴展性和品質。精準醫療方法和個人化醫療策略的日益採用正在推動對具有詳細分子和臨床註釋的生物樣本的需求。生物樣本庫為研究人員和臨床醫生提供全面的樣本收集以進行基因型-表現型相關性、藥物基因組學研究和患者分層工作，在支持精準醫療計劃方面發揮關鍵作用。因此，全球生物樣本庫市場可望持續擴張，為生物樣本庫組織、醫療機構和生命科學公司提供重要機會，為生物醫學研究和治療創新做出貢獻。

主要市場促進因素

高品質生物樣本的需求不斷成長

生物樣本庫技術的進步

慢性病盛行率不斷上升

主要市場挑戰

樣品品質和完整性

數據管理和整合

主要市場趨勢

疾病特異性生物庫的擴展

轉向虛擬生物銀行

細分市場洞察

類型洞察

應用洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球生物樣本庫市場展望

• 市場規模預測
  • 按價值
• 市佔率預測
  • 按類型（面向疾病的生物庫、基於人群的生物庫、組織生物庫、其他）
  • 依樣本類型（血液製品、生物液體、核酸、細胞系、其他）
  • 按應用（治療、藥物發現、臨床診斷、臨床研究）
  • 按最終用戶（學術研究機構、製藥生物技術公司、醫院診所等）
  • 按地區
  • 按公司分類 (2023)
• 市場地圖
  • 按類型
  • 依樣品類型
  • 按申請
  • 按最終用戶
  • 按地區

第 6 章：亞太地區生物樣本庫市場展望

• 市場規模預測
  • 按價值
• 市佔率預測
  • 按類型
  • 依樣品類型
  • 按申請
  • 按最終用戶
  • 按國家/地區
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第 7 章：歐洲生物樣本庫市場展望

• 市場規模預測
  • 按價值
• 市佔率預測
  • 按類型
  • 依樣品類型
  • 按申請
  • 按最終用戶
  • 按國家/地區
• 歐洲：國家分析
  • 法國
  • 英國
  • 義大利
  • 德國
  • 西班牙

第 8 章：北美生物樣本庫市場展望

• 市場規模預測
  • 按價值
• 市佔率預測
  • 按類型
  • 依樣品類型
  • 按申請
  • 按最終用戶
  • 按國家/地區
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第 9 章：南美洲生物樣本庫市場展望

• 市場規模預測
  • 按價值
• 市佔率預測
  • 按類型
  • 依樣品類型
  • 按申請
  • 按最終用戶
  • 按國家/地區
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲生物樣本庫市場展望

• 市場規模預測
  • 按價值
• 市佔率預測
  • 按類型
  • 依樣品類型
  • 按申請
  • 按最終用戶
  • 按國家/地區
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 埃及

第 11 章：市場動態

• 促進要素
• 挑戰

第 12 章：市場趨勢發展

• 最近的發展
• 產品發布
• 併購

第 13 章：全球生物樣本庫市場：SWOT 分析

第 14 章：波特的五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 客戶的力量
• 替代產品的威脅

第 15 章：公司簡介

• 丹納赫公司
  • 商業概覽
  • 公司概況
  • 產品與服務
  • 財務（如果是上市公司）
  • 最近的發展
  • SWOT分析
• 默克公司
• 貝克頓迪金森公司
• 阿萬托公司
• 賽默飛世爾科技公司
• 帝肯貿易公司
• 凱傑公司
• 漢密爾頓公司
• ProMedDx 有限公司
• ISENET 生物銀行有限公司

第 16 章：策略建議

第 17 章：關於我們免責聲明

Global Biobanks Market was valued at USD 75.34 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 8.54% through 2029. The Global Biobanks Market is experiencing substantial growth driven by increasing demand for high-quality biological samples for research, clinical trials, and personalized medicine initiatives. Biobanks serve as repositories for storing various types of biological specimens, including blood, tissues, cells, and DNA, along with associated data such as medical histories and lifestyle information. These repositories play a crucial role in advancing biomedical research, enabling scientists to access large and diverse collections of samples for studying diseases, identifying biomarkers, and developing new therapeutics. One of the key drivers fueling the growth of the Global Biobanks Market is the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions. The need for well-characterized and annotated biospecimens from diverse patient populations is essential for understanding disease mechanisms, discovering novel therapeutic targets, and evaluating treatment responses. Additionally, advancements in biobanking technologies, including automation, robotics, and data management systems, are enhancing the efficiency, scalability, and quality of biobanking operations. The increasing adoption of precision medicine approaches and personalized healthcare strategies is driving the demand for biospecimens with detailed molecular and clinical annotations. Biobanks play a pivotal role in supporting precision medicine initiatives by providing researchers and clinicians with access to comprehensive collections of samples for genotype-phenotype correlations, pharmacogenomics studies, and patient stratification efforts. As a result, the Global Biobanks Market is poised for continued expansion, offering significant opportunities for biobanking organizations, healthcare institutions, and life sciences companies to contribute to biomedical research and therapeutic innovation.

Key Market Drivers

Rising Demand for High-Quality Biological Samples

The Global Biobanks Market is experiencing a surge in demand for high-quality biological samples driven by the increasing need for reliable biospecimens in biomedical research, drug development, and clinical applications. High-quality biological samples are essential for studying disease mechanisms, identifying biomarkers, and developing novel therapeutics, making biobanks indispensable resources in the life sciences industry. One of the primary factors fueling the rising demand for high-quality biological samples is the growing emphasis on precision medicine and personalized healthcare. Precision medicine approaches aim to tailor medical treatments to individual patients based on their genetic makeup, lifestyle factors, and environmental influences. As such, there is a heightened need for biospecimens with detailed molecular and clinical annotations to support genotype-phenotype correlations, pharmacogenomics studies, and patient stratification efforts. The increasing prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions is driving the demand for biospecimens for disease research and therapeutic development. Biobanks provide researchers and clinicians with access to diverse collections of well-characterized biological samples from various patient populations, enabling the investigation of disease etiology, progression, and treatment responses. Advancements in biobanking technologies have also contributed to the rising demand for high-quality biological samples. Automation, robotics, and data management systems have improved the efficiency, scalability, and reliability of biobanking operations, enabling biobanks to store, process, and manage large volumes of biospecimens and associated data with greater precision and consistency. The increasing adoption of biobanking practices in translational research, clinical trials, and population health studies further drives the demand for high-quality biological samples. Biobanks play a crucial role in facilitating collaborations between academia, industry, and healthcare sectors, fostering innovation and accelerating the development of new diagnostics, therapeutics, and personalized medicine approaches. The rising demand for high-quality biological samples underscores the critical role of biobanks in advancing biomedical research and improving patient care, driving growth and expansion in the Global Biobanks Market.

Advancements in Biobanking Technologies

Advancements in biobanking technologies have revolutionized the landscape of the Global Biobanks Market, enhancing the efficiency, scalability, and reliability of biological sample storage, management, and analysis. These technological innovations have propelled the field of biobanking forward, enabling biobanks to meet the growing demands of researchers, clinicians, and pharmaceutical companies for high-quality biospecimens. One significant advancement in biobanking technology is the implementation of automation and robotics systems. Automated sample handling and processing equipment streamline biobanking workflows, reducing human error, increasing throughput, and improving sample integrity. Robotics platforms enable precise and consistent sample retrieval, aliquoting, and storage, ensuring sample quality and minimizing contamination risks. The advancements in data management systems have revolutionized biobank operations by facilitating efficient sample tracking, inventory management, and data integration. Electronic laboratory information management systems (LIMS) and biobanking software solutions enable real-time monitoring of sample locations, conditions, and associated metadata, ensuring traceability and compliance with regulatory requirements. The innovations in sample preservation and storage technologies have expanded the capabilities of biobanks to store diverse types of biological specimens under optimal conditions. State-of-the-art cryopreservation methods, such as automated liquid nitrogen storage systems and vapor-phase nitrogen freezers, ensure long-term sample viability while minimizing degradation and sample loss. The emerging technologies such as blockchain and artificial intelligence (AI) hold promise for enhancing data security, privacy, and analysis capabilities within the biobanking sector. Blockchain-based systems enable secure and transparent management of sample-related transactions and data sharing, while AI algorithms offer powerful tools for data analysis, pattern recognition, and predictive modeling in biobanking research. The advancements in biobanking technologies are driving innovation, efficiency, and collaboration within the Global Biobanks Market, empowering researchers and clinicians to accelerate biomedical research, drug discovery, and personalized medicine initiatives. Continued investments in technology development and infrastructure are expected to further propel the growth and evolution of the biobanking industry in the years to come.

Growing Prevalence of Chronic Diseases

The growing prevalence of chronic diseases is a significant driver shaping the trajectory of the Global Biobanks Market. Chronic diseases, including cancer, cardiovascular disorders, diabetes, and neurological conditions, pose significant public health challenges worldwide, contributing to a substantial burden of morbidity and mortality. As the incidence of chronic diseases continues to rise globally, there is an increasing need for high-quality biological samples to support research efforts aimed at understanding disease mechanisms, identifying biomarkers, and developing effective treatments. Biobanks play a crucial role in addressing the growing prevalence of chronic diseases by providing researchers, clinicians, and pharmaceutical companies with access to diverse collections of well-characterized biological specimens. These biospecimens, which include blood, tissues, cells, and DNA samples, are essential for studying disease etiology, progression, and treatment responses. For instance, biobanks enable researchers to investigate genetic and environmental factors contributing to the development of chronic diseases, facilitating the discovery of novel biomarkers for early detection, prognosis, and personalized treatment approaches. Additionally, biobanks support translational research efforts by providing access to clinical samples from large and diverse patient populations, enabling the validation of new diagnostic tools and therapeutic interventions. The biobanks play a critical role in supporting longitudinal studies and population health research initiatives aimed at identifying risk factors, trends, and disparities in chronic disease prevalence and outcomes. By collecting and analyzing longitudinal data and biospecimens from individuals over time, biobanks contribute valuable insights into disease trajectories, treatment responses, and long-term health outcomes. The growing prevalence of chronic diseases underscores the importance of biobanking in advancing biomedical research, improving clinical care, and addressing global health challenges. Continued investments in biobank infrastructure, technology, and collaboration are essential for meeting the increasing demand for high-quality biological samples and driving innovation in chronic disease prevention, diagnosis, and treatment.

Key Market Challenges

Sample Quality and Integrity

Sample quality and integrity are paramount in the Global Biobanks Market to ensure the reliability and reproducibility of research findings and clinical applications. Challenges related to sample quality and integrity include the risk of degradation over time, variability in sample collection and processing methods, and the potential for contamination. Maintaining sample quality starts with rigorous adherence to standardized protocols for sample collection, processing, and storage. Proper handling techniques, such as ensuring appropriate temperature control and using preservatives, are essential to minimize degradation and maintain sample integrity. The robust quality control measures, including regular sample monitoring, testing for contamination, and validation of sample identity, are crucial for ensuring the accuracy and reliability of stored samples. Biobanks invest in state-of-the-art infrastructure and employ advanced technologies to safeguard sample quality and integrity. These include automated sample handling systems, stringent quality assurance protocols, and comprehensive data management systems to track sample provenance and ensure compliance with regulatory requirements. By prioritizing sample quality and integrity, biobanks can enhance the utility and value of their repositories, enabling researchers, clinicians, and pharmaceutical companies to access high-quality biological specimens for a wide range of biomedical research and clinical applications.

Data Management and Integration

In the Global Biobanks Market, effective data management and integration are critical for maximizing the utility of biological samples and associated data for research and clinical applications. Biobanks collect and store vast amounts of data, including clinical, genetic, and molecular information, alongside biological specimens. Managing and integrating this diverse array of data presents several challenges. One challenge is the need to establish robust data management systems capable of handling large volumes of data while ensuring security, privacy, and compliance with regulatory requirements. Biobanks must implement advanced data storage, retrieval, and sharing mechanisms to facilitate efficient data management across different research projects and collaborations. The integrating data from disparate sources poses challenges related to data harmonization, standardization, and interoperability. Biobanks must adopt standardized data formats, ontologies, and metadata standards to facilitate data integration and enable cross-study comparisons. Advancements in technologies such as cloud computing, artificial intelligence, and blockchain offer opportunities to enhance data management and integration capabilities within the biobanking sector. These technologies enable real-time data processing, analysis, and sharing, improving data accessibility, collaboration, and knowledge discovery. By addressing challenges related to data management and integration, biobanks can unlock the full potential of their repositories, enabling researchers, clinicians, and policymakers to access comprehensive datasets for advancing biomedical research, drug discovery, and personalized medicine initiatives. Collaborative efforts to establish best practices, standards, and infrastructure for data management and integration are essential for driving innovation and accelerating progress in the field of biobanking.

Key Market Trends

Expansion of Disease-specific Biobanks

The expansion of disease-specific biobanks is a significant trend shaping the Global Biobanks Market. These biobanks focus on collecting, storing, and managing biospecimens from patients with specific diseases or conditions, catering to the specialized needs of researchers and clinicians in targeted research areas. One key driver behind the expansion of disease-specific biobanks is the growing recognition of the heterogeneity and complexity of diseases. By focusing on specific diseases or conditions, these biobanks enable researchers to access well-characterized samples that are relevant to their research interests, facilitating more targeted investigations into disease mechanisms, biomarker discovery, and therapeutic development. The disease-specific biobanks play a crucial role in advancing precision medicine initiatives. By collecting biospecimens from patients with specific diseases, these biobanks contribute to the development of personalized treatment strategies tailored to individual patients' genetic makeup, lifestyle factors, and disease characteristics. For example, cancer biobanks collect tumor samples from patients with different types and stages of cancer, enabling researchers to identify biomarkers associated with treatment response and prognosis and develop targeted therapies. Disease-specific biobanks foster collaboration among researchers, clinicians, and patient advocacy groups focused on specific diseases. By providing a centralized repository of biospecimens and associated clinical data, these biobanks facilitate knowledge sharing, data analysis, and resource pooling, accelerating research progress and improving patient outcomes. The expansion of disease-specific biobanks reflects a growing emphasis on precision medicine, personalized healthcare, and collaborative research initiatives within the Global Biobanks Market. Continued investment in disease-specific biobanking infrastructure, technology, and collaboration is essential for addressing the complex challenges associated with various diseases and driving innovation in biomedical research and clinical care...

Shift towards Virtual Biobanking

The Global Biobanks Market is witnessing a notable shift towards virtual biobanking, a trend characterized by the sharing of data and biospecimens across multiple biobanks and research institutions. Virtual biobanking offers several advantages over traditional, centralized biobanking models, including increased collaboration, data sharing, and resource optimization. One of the key drivers behind the shift towards virtual biobanking is the growing recognition of the need for large, diverse datasets to support biomedical research and personalized medicine initiatives. By enabling researchers to access a wider range of samples and data from multiple biobanks, virtual biobanking facilitates more comprehensive and robust analyses, leading to a deeper understanding of disease mechanisms, biomarker discovery, and therapeutic development. The virtual biobanking promotes collaboration and knowledge exchange among researchers, clinicians, and institutions worldwide. By sharing data and resources, researchers can leverage each other's expertise, infrastructure, and sample collections, accelerating research progress and maximizing the impact of limited resources. Virtual biobanking enables biobanks to overcome logistical and ethical challenges associated with sample sharing. By implementing standardized protocols, data sharing agreements, and quality control measures, virtual biobanks ensure the ethical and responsible use of biospecimens and associated data while protecting patient privacy and confidentiality. Virtual biobanking facilitates data integration and analysis across different research projects and institutions, enabling researchers to perform cross-study comparisons, meta-analyses, and validation studies more efficiently. This approach enhances the reproducibility and generalizability of research findings and promotes transparency and accountability within the scientific community. The shift towards virtual biobanking reflects a growing emphasis on collaboration, data sharing, and innovation in the Global Biobanks Market. Continued investment in virtual biobanking infrastructure, technology, and governance frameworks is essential for realizing the full potential of this transformative approach in advancing biomedical research and improving patient care.

Segmental Insights

Type Insights

Based ontype,disease-oriented biobanks segment dominated the Global Biobanks Market in 2023.This is ascribed to the specialized focus on collecting biospecimens from patients with specific diseases or conditions. This targeted approach facilitates in-depth research into disease mechanisms, biomarker discovery, and therapeutic development, catering to the diverse needs of researchers and clinicians. Disease-oriented biobanks enable precision medicine initiatives by providing well-characterized samples relevant to individual diseases, driving advancements in personalized healthcare. Additionally, the collaborative nature of disease-oriented biobanks fosters partnerships among researchers, clinicians, and patient advocacy groups, further enhancing their prominence in the biobanking landscape.

Application Insights

Based on application, drug discovery segment dominated the Global Biobanks Market in 2023. This is ascribed due to due to the increasing demand for high-quality biological samples to support drug development efforts. Biobanks provide researchers with access to diverse collections of well-characterized biospecimens, enabling the identification of novel drug targets, evaluation of drug efficacy and safety, and optimization of therapeutic interventions. Additionally, advancements in biobanking technologies and collaborations between biobanks and pharmaceutical companies further bolster the role of biobanks in drug discovery. The potential to accelerate the drug development process and bring new treatments to market drives significant investment and focus on the Drug Discovery segment within the Global Biobanks Market.

Regional Insights

North America leads the Global Biobanks Market, due to several factors. The region boasts advanced healthcare infrastructure and significant investments in biomedical research, fostering the establishment of numerous high-quality biobanks. North America is home to many leading pharmaceutical and biotechnology companies, driving demand for biological samples for drug discovery and development. The supportive regulatory frameworks and strong academic and research institutions contribute to the region's leadership in biobanking. The presence of a highly skilled workforce and a culture of innovation further strengthens North America's position in the Global Biobanks Market. Overall, the combination of robust infrastructure, industry expertise, regulatory support, and research capabilities makes North America a dominant player in the biobanking landscape.

Key Market Players

Danaher Corporation

Merck KgaA

Becton, Dickinson, and Company

Avantor, Inc.

Thermo Fisher Scientific, Inc

Tecan Trading AG

QIAGEN N.V.

Hamilton Company

ProMedDx, LLC

ISENET Biobanking S.r.l

Report Scope:

In this report, the Global Biobanks Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Biobanks Market,By Type:

• Disease Oriented Biobanks
• Population Based Biobanks
• Tissue Biobanks
• Others

Global Biobanks Market,By Sample Type:

• Blood Products
• Biological Fluids
• Nucleic Acid
• Cell Lines
• Others

Global Biobanks Market,ByApplication:

• Therapeutics
• Drug Discovery
• Clinical Diagnostics
• Clinical Research

Global Biobanks Market,ByEnd User:

• Academic Research Institutes
• Pharmaceutical Biotechnology Companies
• Hospitals Clinics
• Others

Global Biobanks Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Biobanks Market.

Available Customizations:

Global Biobanks Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

• 1.1.Market Definition
• 1.2.Scope of the Market
  • 1.2.1.Markets Covered
  • 1.2.2.Years Considered for Study
  • 1.2.3.Key Market Segmentations

2.Research Methodology

• 2.1.Objective of the Study
• 2.2.Baseline Methodology
• 2.3.Key Industry Partners
• 2.4.Major Association and Secondary Sources
• 2.5.Forecasting Methodology
• 2.6.Data Triangulation Validation
• 2.7.Assumptions and Limitations

3.Executive Summary

• 3.1.Overview of the Market
• 3.2.Overview of Key Market Segmentations
• 3.3.Overview of Key Market Players
• 3.4.Overview of Key Regions/Countries
• 3.5.Overview of Market Drivers, Challenges, Trends

4.Voice of Customer

5.Global Biobanks Market Outlook

• 5.1.Market Size Forecast
  • 5.1.1.By Value
• 5.2.Market Share Forecast
  • 5.2.1.By Type (Disease Oriented Biobanks, Population Based Biobanks, Tissue Biobanks, Others)
  • 5.2.2.By Sample Type (Blood Products, Biological Fluids, Nucleic Acid, Cell Lines, Others)
  • 5.2.3.By Application (Therapeutics, Drug Discovery, Clinical Diagnostics, Clinical Research)
  • 5.2.4.By End User (Academic Research Institutes, Pharmaceutical Biotechnology Companies, Hospitals Clinics, Others)
  • 5.2.5.By Region
  • 5.2.6.By Company (2023)
• 5.3.Market Map
  • 5.3.1.By Type
  • 5.3.2.By Sample Type
  • 5.3.3.By Application
  • 5.3.4.By End User
  • 5.3.5.By Region

6.Asia Pacific Biobanks Market Outlook

• 6.1.Market Size Forecast
  • 6.1.1.By Value
• 6.2.Market Share Forecast
  • 6.2.1.By Type
  • 6.2.2.By Sample Type
  • 6.2.3.By Application
  • 6.2.4.By End User
  • 6.2.5.By Country
• 6.3.Asia Pacific: Country Analysis
  • 6.3.1.China Biobanks Market Outlook
    • 6.3.1.1.Market Size Forecast
      • 6.3.1.1.1.By Value
    • 6.3.1.2.Market Share Forecast
      • 6.3.1.2.1.By Type
      • 6.3.1.2.2.By Sample Type
      • 6.3.1.2.3.By Application
      • 6.3.1.2.4.By End User
  • 6.3.2.India Biobanks Market Outlook
    • 6.3.2.1.Market Size Forecast
      • 6.3.2.1.1.By Value
    • 6.3.2.2.Market Share Forecast
      • 6.3.2.2.1.By Type
      • 6.3.2.2.2.By Sample Type
      • 6.3.2.2.3.By Application
      • 6.3.2.2.4.By End User
  • 6.3.3.Japan Biobanks Market Outlook
    • 6.3.3.1.Market Size Forecast
      • 6.3.3.1.1.By Value
    • 6.3.3.2.Market Share Forecast
      • 6.3.3.2.1.By Type
      • 6.3.3.2.2.By Sample Type
      • 6.3.3.2.3.By Application
      • 6.3.3.2.4.By End User
  • 6.3.4.South Korea Biobanks Market Outlook
    • 6.3.4.1.Market Size Forecast
      • 6.3.4.1.1.By Value
    • 6.3.4.2.Market Share Forecast
      • 6.3.4.2.1.By Type
      • 6.3.4.2.2.By Sample Type
      • 6.3.4.2.3.By Application
      • 6.3.4.2.4.By End User
  • 6.3.5.Australia Biobanks Market Outlook
    • 6.3.5.1.Market Size Forecast
      • 6.3.5.1.1.By Value
    • 6.3.5.2.Market Share Forecast
      • 6.3.5.2.1.By Type
      • 6.3.5.2.2.By Sample Type
      • 6.3.5.2.3.By Application
      • 6.3.5.2.4.By End User

7.Europe Biobanks Market Outlook

• 7.1.Market Size Forecast
  • 7.1.1.By Value
• 7.2.Market Share Forecast
  • 7.2.1.By Type
  • 7.2.2.By Sample Type
  • 7.2.3.By Application
  • 7.2.4.By End User
  • 7.2.5.By Country
• 7.3.Europe: Country Analysis
  • 7.3.1.France Biobanks Market Outlook
    • 7.3.1.1.Market Size Forecast
      • 7.3.1.1.1.By Value
    • 7.3.1.2.Market Share Forecast
      • 7.3.1.2.1.By Type
      • 7.3.1.2.2.By Sample Type
      • 7.3.1.2.3.By Application
      • 7.3.1.2.4.By End User
  • 7.3.2.United Kingdom Biobanks Market Outlook
    • 7.3.2.1.Market Size Forecast
      • 7.3.2.1.1.By Value
    • 7.3.2.2.Market Share Forecast
      • 7.3.2.2.1.By Type
      • 7.3.2.2.2.By Sample Type
      • 7.3.2.2.3.By Application
      • 7.3.2.2.4.By End User
  • 7.3.3.Italy Biobanks Market Outlook
    • 7.3.3.1.Market Size Forecast
      • 7.3.3.1.1.By Value
    • 7.3.3.2.Market Share Forecast
      • 7.3.3.2.1.By Type
      • 7.3.3.2.2.By Sample Type
      • 7.3.3.2.3.By Application
      • 7.3.3.2.4.By End User
  • 7.3.4.Germany Biobanks Market Outlook
    • 7.3.4.1.Market Size Forecast
      • 7.3.4.1.1.By Value
    • 7.3.4.2.Market Share Forecast
      • 7.3.4.2.1.By Type
      • 7.3.4.2.2.By Sample Type
      • 7.3.4.2.3.By Application
      • 7.3.4.2.4.By End User
  • 7.3.5.Spain Biobanks Market Outlook
    • 7.3.5.1.Market Size Forecast
      • 7.3.5.1.1.By Value
    • 7.3.5.2.Market Share Forecast
      • 7.3.5.2.1.By Type
      • 7.3.5.2.2.By Sample Type
      • 7.3.5.2.3.By Application
      • 7.3.5.2.4.By End User

8.North America Biobanks Market Outlook

• 8.1.Market Size Forecast
  • 8.1.1.By Value
• 8.2.Market Share Forecast
  • 8.2.1.By Type
  • 8.2.2.By Sample Type
  • 8.2.3.By Application
  • 8.2.4.By End User
  • 8.2.5.By Country
• 8.3.North America: Country Analysis
  • 8.3.1.United States Biobanks Market Outlook
    • 8.3.1.1.Market Size Forecast
      • 8.3.1.1.1.By Value
    • 8.3.1.2.Market Share Forecast
      • 8.3.1.2.1.By Type
      • 8.3.1.2.2.By Sample Type
      • 8.3.1.2.3.By Application
      • 8.3.1.2.4.By End User
  • 8.3.2.Canada Biobanks Market Outlook
    • 8.3.2.1.Market Size Forecast
      • 8.3.2.1.1.By Value
    • 8.3.2.2.Market Share Forecast
      • 8.3.2.2.1.By Type
      • 8.3.2.2.2.By Sample Type
      • 8.3.2.2.3.By Application
      • 8.3.2.2.4.By End User
  • 8.3.3.Mexico Biobanks Market Outlook
    • 8.3.3.1.Market Size Forecast
      • 8.3.3.1.1.By Value
    • 8.3.3.2.Market Share Forecast
      • 8.3.3.2.1.By Type
      • 8.3.3.2.2.By Sample Type
      • 8.3.3.2.3.By Application
      • 8.3.3.2.4.By End User

9.South America Biobanks Market Outlook

• 9.1.Market Size Forecast
  • 9.1.1.By Value
• 9.2.Market Share Forecast
  • 9.2.1.By Type
  • 9.2.2.By Sample Type
  • 9.2.3.By Application
  • 9.2.4.By End User
  • 9.2.5.By Country
• 9.3.South America: Country Analysis
  • 9.3.1.Brazil Biobanks Market Outlook
    • 9.3.1.1.Market Size Forecast
      • 9.3.1.1.1.By Value
    • 9.3.1.2.Market Share Forecast
      • 9.3.1.2.1.By Type
      • 9.3.1.2.2.By Sample Type
      • 9.3.1.2.3.By Application
      • 9.3.1.2.4.By End User
  • 9.3.2.Argentina Biobanks Market Outlook
    • 9.3.2.1.Market Size Forecast
      • 9.3.2.1.1.By Value
    • 9.3.2.2.Market Share Forecast
      • 9.3.2.2.1.By Type
      • 9.3.2.2.2.By Sample Type
      • 9.3.2.2.3.By Application
      • 9.3.2.2.4.By End User
  • 9.3.3.Colombia Biobanks Market Outlook
    • 9.3.3.1.Market Size Forecast
      • 9.3.3.1.1.By Value
    • 9.3.3.2.Market Share Forecast
      • 9.3.3.2.1.By Type
      • 9.3.3.2.2.By Sample Type
      • 9.3.3.2.3.By Application
      • 9.3.3.2.4.By End User

10.Middle East and Africa Biobanks Market Outlook

• 10.1.Market Size Forecast
  • 10.1.1.By Value
• 10.2.Market Share Forecast
  • 10.2.1.By Type
  • 10.2.2.By Sample Type
  • 10.2.3.By Application
  • 10.2.4.By End User
  • 10.2.5.By Country
• 10.3.MEA: Country Analysis
  • 10.3.1.South Africa Biobanks Market Outlook
    • 10.3.1.1.Market Size Forecast
      • 10.3.1.1.1.By Value
    • 10.3.1.2.Market Share Forecast
      • 10.3.1.2.1.By Type
      • 10.3.1.2.2.By Sample Type
      • 10.3.1.2.3.By Application
      • 10.3.1.2.4.By End User
  • 10.3.2.Saudi Arabia Biobanks Market Outlook
    • 10.3.2.1.Market Size Forecast
      • 10.3.2.1.1.By Value
    • 10.3.2.2.Market Share Forecast
      • 10.3.2.2.1.By Type
      • 10.3.2.2.2.By Sample Type
      • 10.3.2.2.3.By Application
      • 10.3.2.2.4.By End User
  • 10.3.3.UAE Biobanks Market Outlook
    • 10.3.3.1.Market Size Forecast
      • 10.3.3.1.1.By Value
    • 10.3.3.2.Market Share Forecast
      • 10.3.3.2.1.By Type
      • 10.3.3.2.2.By Sample Type
      • 10.3.3.2.3.By Application
      • 10.3.3.2.4.By End User
  • 10.3.4.Egypt Biobanks Market Outlook
    • 10.3.4.1.Market Size Forecast
      • 10.3.4.1.1.By Value
    • 10.3.4.2.Market Share Forecast
      • 10.3.4.2.1.By Type
      • 10.3.4.2.2.By Sample Type
      • 10.3.4.2.3.By Application
      • 10.3.4.2.4.By End User

11.Market Dynamics

• 11.1.Drivers
• 11.2.Challenges

12.Market Trends Developments

• 12.1.Recent Developments
• 12.2.Product Launches
• 12.3.Mergers Acquisitions

13.Global Biobanks Market: SWOT Analysis

14.Porter's Five Forces Analysis

• 14.1.Competition in the Industry
• 14.2.Potential of New Entrants
• 14.3.Power of Suppliers
• 14.4.Power of Customers
• 14.5.Threat of Substitute Product

15.Company Profile

• 15.1.Danaher Corporation
  • 15.1.1.Business Overview
  • 15.1.2.Company Snapshot
  • 15.1.3.Products Services
  • 15.1.4.Financials (In case of listed)
  • 15.1.5.Recent Developments
  • 15.1.6.SWOT Analysis
• 15.2.Merck KGaA
• 15.3.Becton, Dickinson, and Company
• 15.4.Avantor, Inc.
• 15.5.Thermo Fisher Scientific, Inc
• 15.6.Tecan Trading AG
• 15.7.QIAGEN N.V.
• 15.8.Hamilton Company
• 15.9.ProMedDx, LLC
• 15.10.ISENET Biobanking S.r.l

16.Strategic Recommendations

17. About Us Disclaimer